



KOTHARI PHYTOCHEMICALS & INDUSTRIES LTD.

CIN : L15491WB1897PLC001365

Phone : 91-33-2230-2331/6
91-33-2230-4184
E-mail : hokothari@yahoo.com



REGD. OFFICE :
C-4, GILLANDER HOUSE
8, NETAJI SUBHAS ROAD
KOLKATA-700 001
INDIA

Ref: KPIL / 2017 - 18 / CSE / 157

February 14, 2018

The Secretary
The Calcutta Stock Exchange Limited
7, Lyons Range
KOLKATA - 700 001

Dear Sir,

Sub. : Unaudited Financial Results for the Quarter and Nine months ended 31st December, 2017 and Limited Review Report thereon.

**CSE Stock Code : Physical - 21160 & Demat - 10021160
ISIN : INE264E01016**

Pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (LODR), please find enclosed herewith a copy of the Unaudited Financial Results of the Company alongwith Segment - wise Revenue, Results, Assets & Liabilities, prepared in accordance with Ind - AS adopted for the first time, for the Quarter and Nine months ended 31 December, 2017 as reviewed by the Audit Committee and approved by the Board of Directors in their meeting held on today i.e. 14th February, 2018.

FURTHER also find enclosed copy of the Limited Review Report dated 14th February, 2018 on the Unaudited Financial Results of the Company for the Quarter and Nine months ended 31st December, 2017, given by the statutory auditors of the Company K. Ray & Company, Chartered Accountants.

FURTHER pursuant to Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed copy of Extract of Unaudited Financial Results for the Quarter and Nine months ended 31st December, 2017 to be published in the newspapers as per above said Regulation.

Please take the above on your record.

Thanking you,


Yours faithfully,

For **KOTHARI PHYTOCHEMICALS & INDUSTRIES LTD.**


M. L. Daga
(FCS - 2650)

Company Secretary cum Compliance Officer

Encl.: As above





KOTHARI PHYTOCHEMICALS & INDUSTRIES LIMITED

CIN : L15491WB1897PLC001365


Regd. Office : C - 4, Gillander House, 8 Netaji Subhas Road, Kolkata - 700 001

Phone : 2230 - 2331 (6 lines), E.mail : hokothari@yahoo.com

Website : www.kothariphyto.com

Statement of Unaudited Financial Results for the Quarter and Nine months ended on 31st December, 2017. (₹ in lakh)

Sl. No.	Particulars	Quarter Ended			Nine Months Ended	
		31-12-2017 (Unaudited)	30-09-2017 (Unaudited)	31-12-2016 (Unaudited)	31-12-2017 (Unaudited)	31-12-2016 (Unaudited)
1.	Income					
(a)	Revenue from Operations	514.40	412.03	584.05	1,680.31	1,744.18
(b)	Other income	92.14	57.92	(15.14)	189.08	124.01
	Total income	606.54	469.95	568.91	1,869.39	1,868.19
2.	Expenses					
(a)	Cost of Materials consumed	248.82	214.25	144.92	714.51	543.62
(b)	Purchase of Stock - in - trade	-	114.24	-	114.24	-
(c)	Changes in inventories of finished goods, work - in - progress and stock - in - trade	32.71	(127.90)	174.33	(47.22)	342.31
(d)	Excise Duty	-	-	25.69	19.23	67.70
(e)	Employee benefits expense	78.20	67.32	69.24	222.58	207.64
(f)	Finance costs	1.86	0.50	3.29	6.33	5.67
(g)	Depreciation and amortisation expense	23.46	23.46	24.18	70.38	72.38
(h)	Power and fuel	28.96	25.68	19.09	81.96	75.72
(i)	Other expenditure	49.74	56.40	88.28	174.78	213.23
	Total expenses	463.75	373.95	549.02	1,356.79	1,528.47
3.	Profit / (Loss) before exceptional items and Tax (1-2)	142.79	96.00	19.89	512.60	339.72
4.	Exceptional Items	-	-	-	-	-
5.	Profit / (Loss) before Tax from continuing operations (3-4)	142.79	96.00	19.89	512.60	339.72
6.	Tax expense	34.00	18.00	19.00	140.00	95.00
7.	Net Profit / (Loss) for the period from continuing operations (5-6)	108.79	78.00	0.89	372.60	244.72
8.	Profit / (Loss) before Tax from discontinued operations	446.35	(10.64)	-	435.07	-
9.	Tax expenses / (credit) of discontinued operations	32.00	(4.00)	-	28.00	-
10.	Net Profit / (Loss) from discontinued operations (8-9)	414.35	(6.64)	-	407.07	-
11.	Profit / (Loss) for the period (7+10)	523.14	71.36	0.89	779.67	244.72
12.	Other Comprehensive Income not to be reclassified to Profit and Loss in subsequent periods (net of tax)	-	-	-	-	-
13.	Total Comprehensive Income for the period (11+12)	523.14	71.36	0.89	779.67	244.72
14.	Paid - up equity share capital (Face Value of ₹ 10/- each)	388.32	388.32	388.32	388.32	388.32
15.	Earnings / (Loss) per Equity Share of Face Value of ₹ 10/- each) (not annualised) :					
	For Continuing Operations :					
	Basic and Diluted	2.80	2.01	0.02	9.60	6.30
	For Discontinued Operations :					
	Basic and Diluted	10.67	(0.17)	-	10.48	-
	For Continuing and Discontinued Operations :					
	Basic and Diluted	13.47	1.84	0.02	20.08	6.30



Unaudited Segment wise Revenue, Results, Assets and Liabilities for the Quarter and Nine months ended 31st December, 2017

(₹ in lakh)

Particulars	Quarter Ended			Nine Months Ended	
	31-12-2017	30-09-2017	31-12-2016	31-12-2017	31-12-2016
	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)
1. Segment Revenue					
A) Continuing Operations :					
(a) Bulk Drugs	343.52	230.39	327.04	1,154.77	1,058.19
(b) Chemicals	170.88	181.64	257.01	525.54	685.99
(c) Unallocated	-	-	-	-	-
Total	514.40	412.03	584.05	1,680.31	1,744.18
Less: Inter Segment Revenue	-	-	-	-	-
Net Sales / Income from Continuing Operations	514.40	412.03	584.05	1,680.31	1,744.18
B) Net Sales / Income from Discontinued Operations (Chemicals)	0.00	-	-	14.05	-
2. Segment Results (Profit) (+) / Loss (-) before tax and interest from each segment)					
A) Continuing Operations :					
(a) Bulk Drugs	66.60	57.86	55.21	398.04	275.56
(b) Chemicals	20.00	16.78	23.12	38.13	52.75
(c) Unallocated	81.52	45.27	(30.98)	153.14	89.66
Total	168.12	119.91	47.35	589.31	417.97
Less: i) Finance Costs	1.86	0.50	3.29	6.33	5.87
ii) Other Un-allocable Expenditure net off unallocable income	23.47	23.41	24.17	70.38	72.38
Total Profit / (Loss) Before Tax from Continuing Operations	142.79	96.00	19.89	512.60	339.72
B) Total Profit / (Loss) from Discontinued Operations (Chemicals)	446.35	(10.64)	-	435.07	-
3. Segment Assets					
(a) Bulk Drugs	2,132.58	2,339.05	1,939.95	2,132.58	1,939.95
(b) Chemicals					
(i) Continuing Operations	406.12	382.45	640.98	406.12	640.98
(ii) Discontinued Operations	1.79	116.56	-	1.79	-
(c) Unallocated	2,979.42	2,793.45	2,187.84	2,979.42	2,187.84
Total Segment Assets	5,519.91	5,631.51	4,768.77	5,519.91	4,768.77
4. Segment Liabilities					
(a) Bulk Drugs	154.81	387.37	147.02	154.81	147.02
(b) Chemicals					
(i) Continuing Operations	125.24	111.18	158.42	125.24	158.42
(ii) Discontinued Operations	0.83	58.14	-	0.83	-
(c) Unallocated	50.75	409.68	56.40	50.75	56.40
Total Segment Liabilities	331.63	966.37	361.84	331.63	361.84

- Notes
- The above results were reviewed by the Audit Committee and taken on record by the Board of Directors of the Company at their respective meetings held on February 14, 2018. The Limited Review of the above results for the Quarter and Nine months ended December 31, 2017 has been carried out by the Statutory Auditors.
 - The Company has adopted Indian Accounting Standard (Ind AS) prescribed under Section 133 of the Companies Act, 2013, read with the relevant rules issued thereunder, from April 1, 2016 being the date of transition as per Ind AS 101. Accordingly, these unaudited financial results have been prepared in accordance with the recognition and measurement principles laid down in Ind AS 34 "Interim Financial Reporting" and the other accounting principles generally accepted in India.
 - The financial results and other financial information for the Quarter and Nine months ended December 31, 2016 have been compiled by the management as per Ind AS, after exercising necessary due diligence, to ensure that the financial results provide true and fair view of the results in accordance with Ind AS. This information has not been subject to any limited review or audit.
 - The Company has discontinued the operation of its Southern Synthetics Division during the quarter ended 30th September, 2017. Income and other expenses of this Division has been disclosed as are required as per Ind AS.
 - During the Quarter under Review, the assets relating to Southern Synthetics Division of the Company have been sold / disposed off. Net gain on such sale / disposal amounts to ₹ 452.33 Lakh has been included under "Net Profit / (Loss) from discontinued operations" as shown in item 10 above.
 - The reconciliation of net profit in accordance with Indian GAAP (referred to as "Previous GAAP") to total comprehensive income in accordance with Ind AS is as under :

Particulars	(₹ in lakh)	
	Quarter ended 31.12.2016 (Refer Note 3)	Nine months ended 31.12.2016 (Refer Note 3)
Net Profit as per Previous Indian GAAP	48.36	208.53
Add / (Less) : Adjustment on account of :		
Fair Valuation of Financial Assets	(47.46)	36.13
Provision for Expected Credit Losses on Trade Receivable	(0.01)	0.06
Net Profit as per Ind AS	0.89	244.72
Other Comprehensive Income (Net of Tax)	-	-
Total Comprehensive Income for the period	0.89	244.72

- Post applicability of Goods and Service Tax (GST) w. e. f. July 1, 2017. Revenue from operations is disclosed net of GST. However, revenue for the period upto June 30, 2017 is inclusive of Excise duty. Accordingly, revenue from operations and other expenses for the quarter and nine months ended December 31, 2017 are not comparable with the previous periods presented in the results.
- The results of the Company are available at www.cse-india.com and www.kothariphyto.com.
- Previous period's figures have been regrouped / rearranged wherever necessary to conform to the current period's classification.

Place **Kolkata**
Date **14th February, 2018**

A. K. TOSHNIWAL
Managing Director
(DIN: 06872891)





REVIEW REPORT TO

THE BOARD OF DIRECTORS OF KOTHARI PHYTOCHEMICALS & INDUSTRIES LIMITED

1. We have reviewed the accompanying Statement of Unaudited Financial Results of **KOTHARI PHYTOCHEMICALS & INDUSTRIES LIMITED** ("the Company"), for the Quarter and Nine Months ended 31st December, 2017 ("the Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as modified by Circular No. CIR / CFD / FAC / 62 / 2016 dated 5th July, 2016.

This Statement which is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to issue a report on the Statement based on our review.

2. The reports on Review of Interim Financial Results of Phytochemicals Division, Southern Synthetics Division and Claro India Division carried out by Messrs. Jitendra K Agarwal & Associates have been taken into account for the purpose of preparing our report.
3. We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement.
4. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
5. We invite your attention to the following:
 - (a) Deferred Tax charge / release, if any, for the purpose of compilation of the aforesaid Statement will be recognized in the annual accounts of the Company as per consistent practice followed by them.
 - (b) The Company is consistently providing for Gratuity and Leave liability for its employees in its annual accounts and accordingly these have not been recognized for the purpose of the compilation of the aforesaid statement.

Cont. P / 2




E-mail : kray.co1@gmail.com

4, Ripon Street, (2nd Floor) Kolkata - 700 016, Tel : 2229-7940, 2229-3950, Fax : 91-33-2265 1762

- (c) Note 2 to the Statement which states that the Company has adopted Ind AS for the financial year commencing from April 1, 2017, and accordingly, the Statement has been prepared by the Company's Management in compliance with Ind AS.
6. Based on our review conducted as above and read with our comments in paragraph 5 above, nothing has come to our attention that causes us to believe that the Statement has not been prepared in all material respects in accordance with Ind AS and other recognized accounting practices and policies, and has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, 2015 and SEBI circular dated 5th July, 2016, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For K. RAY & COMPANY
Chartered Accountants
(Firm's Registration No. 312142E)



Supratim Roychoudhury
Partner
Membership No.: 066040

Kolkata, 14th February, 2018





KOTHARI PHYTOCHEMICALS & INDUSTRIES LIMITED

CIN : L15491WB1897PLC001365

Regd. Office : C - 4, Gillander House, 8 Netaji Subhas Road, Kolkata - 700 001

Phone : 2230 - 2331 (6 lines), E.mail : hokothari@yahoo.com

Website : www.kothariphyto.com

Extract of Unaudited Financial Results for the Quarter and Nine Months ended 31st December, 2017

(₹ in lakh)

Sl. No.	Particulars	Quarter Ended			Nine Months ended	
		31-12-2017	30-09-2017	31-12-2016	31-12-2017	31-12-2016
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)
1.	Total Income from Operations	606.54	469.95	568.91	1869.39	1868.19
2.	Net Profit for the period (before Tax, Exceptional and / or Extraordinary items)	142.79	96.00	19.89	512.60	339.72
3.	Net Profit for the period before tax (after Exceptional and / or Extraordinary items)	142.79	96.00	19.89	512.60	339.72
4.	Net Profit for the period after tax (after Exceptional and/ or Extraordinary items)	108.79	78.00	0.89	372.60	244.72
5.	Net Profit / (Loss) from discontinued operations	414.35	(6.64)	0.00	407.07	0.00
6.	Other comprehensive income (net of tax)	0.00	0.00	0.00	0.00	0.00
7.	Total Comprehensive Income for the period	523.14	71.36	0.89	779.67	244.72
8.	Equity Share Capital (Face value Rs. 10/- each)	388.32	388.32	388.32	388.32	388.32
9.	Earnings Per Equity Share (of Rs. 10/- each) (not annualised) :					
	For Continuing Operations :					
	Basic and Diluted	2.80	2.01	0.02	9.60	6.30
	For Discontinued Operations :					
	Basic and Diluted	10.67	(0.17)	0.00	10.48	0.00
	For Continuing and Discontinued Operations :					
	Basic and Diluted	13.47	1.84	0.02	20.08	6.30

Notes:

- The above is an extract of the detailed format of Quarterly and Nine Months Unaudited Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing and Other Disclosure Requirements) Regulations, 2015. The full format of the Quarterly and Nine months Unaudited Financial Results are available on the Calcutta Stock Exchange website (www.cse-india.com) and on the Company's website (www.kothariphyto.com)
- The financials has been prepared in accordance with Companies (Indian Accounting Standards) Rules 2015 IND - AS to the extent applicable. The Company has adopted IND - AS beginning from 1st April, 2017 with transition date of 1st April, 2016, for the first time.
- The Company has discontinued the operation of its Southern Synthetics Division during the quarter ended 30th September, 2017. Income and other expenses of this Division has been disclosed as are required as per Ind AS.
- During the Quarter under Review, the assets relating to Southern Synthetics Division of the Company have been sold / disposed off. Net gain on such sale / disposal amounts to ₹ 452.33 Lakh has been included under "Net Profit / (Loss) from discontinued operations" as shown in item 5 above.
- The reconciliation of net profit in accordance with Indian GAAP (referred to as "Previous GAAP") to total comprehensive income in accordance with Ind AS is as under:

(₹ in lakh)

Particulars	Quarter ended	Nine months ended
	31-12-2016	31-12-2016
Net Profit as per Previous Indian Gaap	48.36	208.53
Add / (Less) : Adjustment on account of :		
Fair Valuation of Financial Assets	(47.46)	36.13
Provision for Expected Credit Losses on Trade Receivables	(0.01)	0.06
Net Profit as per Ind AS	0.89	244.72
Other Comprehensive Income (Net of Tax)	-	-
Total Comprehensive income for the period	0.89	244.72

- Previous period's figures have been regrouped / rearranged wherever necessary to conform to the current period's classification.

By order of the Board
For Kothari Phytochemicals & Industries Limited


A. K. TOSHWAL
Managing Director
(DIN : 06872891)

Place : Kolkata

Date : 14th February, 2018